[Metabolic radiotherapy: what role will it have in 2001?].
Metabolic radiotherapy is a new therapy for management of bone pain in patients with bone metastatic prostate carcinoma. Strontium-89 and Samarium-153 concentrate in bone metastases and radiate them. A pain decrease is obtained in 60-70% of cases. Side effects are a significant hematological depression without great clinical consequences if good therapeutic indications are respected. Our multidisciplinary experience of these radionuclides in 54 performed treatments shows a rate of good responders of 66% with a rate of excellent results (total decrease of pain) in 47%. The therapeutic effectiveness is correlated with pain intensity measured by Visual Analogic Scale (VAS) and equivalent dose of morphine. Radionuclide therapy should be applied to patients as early as possible after establishment of bone metastases.
Unité douleur, département d'anesthésie-réanimation, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75475 Paris, France.
B
B
George
M C
MC
Douard
J D
JD
Rain
D000230:Adenocarcinoma / Q000453:epidemiology / Q000378:metabolism / Q000532:radiotherapy* / Q000556:secondary; D000368:Aged; D000369:Aged, 80 and over; D000701:Analgesics, Opioid / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000453:epidemiology / Q000378:metabolism / Q000532:radiotherapy* / Q000556:secondary*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005544:Forecasting; D005602:France / Q000453:epidemiology; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D009943:Organophosphorus Compounds / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D010146:Pain / Q000188:drug therapy / Q000209:etiology / Q000532:radiotherapy; D010166:Palliative Care; D010761:Phosphorus Radioisotopes / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000453:epidemiology / Q000532:radiotherapy*; D011868:Radioisotopes / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D019275:Radiopharmaceuticals / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D012211:Rhenium / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D012493:Samarium / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D013324:Strontium / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D013326:Strontium Radioisotopes / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D016896:Treatment Outcome
D000701:Analgesics, Opioid; D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; D010761:Phosphorus Radioisotopes; D011868:Radioisotopes; D019275:Radiopharmaceuticals; D013326:Strontium Radioisotopes; D012493:Samarium; D012211:Rhenium; C061972:samarium Sm-153 lexidronam; C025700:strontium chloride; D013324:Strontium